UBS Knock-Out AZN/ DE000UM8QCH9 /
23/12/2024 9:50:43 | Diferencia-0.13 | Bid22:00:19 | Ask22:00:19 | Subyacente | Precio de ejercicio | Fecha de expiración | Tipo de opción |
---|---|---|---|---|---|---|---|
4.23EUR | -2.98% | - Volumen de oferta: - |
- Tamaño/ Volumen/ Formato de Ask: - |
AstraZeneca PLC | 108.9872 USD | 31/12/2078 | Put |
Newsfile Corp
23/12
ROSEN, NATIONAL INVESTOR COUNSEL, Encourages AstraZeneca PLC Investors to Secure Counsel Before Impo...
Newsfile Corp
21/12
ROSEN, A LEADING LAW FIRM, Encourages AstraZeneca PLC Investors to Inquire About Securities Class Ac...
Newsfile Corp
20/12
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages AstraZeneca PLC Investors to Inquire About Securities Cla...
Newsfile Corp
18/12
ROSEN, LEADING INVESTOR COUNSEL, Encourages AstraZeneca PLC Investors to Inquire About Securities Cl...
GlobeNewswire
13/08
Artelo Biosciences Reports Second Quarter 2024 Financial Results and Provides Business Update
GlobeNewswire
20/06
Pancreatic Cancer Market Is Projecting to Expand As NCI-Funded Research Expects to Empower Market Gr...
GlobeNewswire
15/05
Fortress Biotech Reports First Quarter 2024 Financial Results and Recent Corporate Highlights
GlobeNewswire
13/05
Artelo Biosciences Reports First Quarter 2024 Financial Results and Provides Business Update
GlobeNewswire
08/05
Mitigating Muscle Loss Becoming More Vital, Global Cancer Cachexia Market Projected to Reach $3.3 Bi...
GlobeNewswire
01/04
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: AdTheorent ...
GlobeNewswire
25/03
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Agiliti, In...
GlobeNewswire
25/03
Artelo Biosciences Reports Fiscal 2023 Year-End Financial Results and Provides Business Update
- Primera página
- Atrás
- 1
- 2
- 3
- 4
- Siguiente
- Última página